Murilo Freitas – Página 52

Exela Pharma Sciences, LLC Expands Voluntary Nationwide Recall of Sodium Bicarbonate Injection, USP, 8.4%, 50 mEq/50 mL Vial, 20-Count Carton due to Vial Breakage UPDATED November 28, 2022

Murilo Freitas - 05:00, 28 de noviembre de 20221,767

Lenoir, North Carolina. Exela Pharma Sciences, LLC, (Exela) is expanding their recall, adding fourteen (14) lots to the ongoing voluntary recall of forty-nine (49) lots of Sodium Bicarbonate Injection, USP, 8.4%, 50 mEq/50 mL vial, 20-count carton. A total of 63 lots are now being recalled to the c

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/exela-pharma-sciences-llc-expands-voluntary-nationwide-recall-sodium-bicarbonate-injection-usp-84-50

rss-es

Baxter Hillrom Recalls WatchCare Incontinence Management System (IMS) for Risk of RF Interference with Nearby Medical Equipment

Murilo Freitas - 05:00, 22 de noviembre de 20221,883

The WatchCare IMS includes hospital beds and disposable incontinence pads. Radiofrequency emissions from the system may interfere with other medical devices.

http://www.fda.gov/medical-devices/medical-device-recalls/baxter-hillrom-recalls-watchcare-incontinence-management-system-ims-risk-rf-interference-nearby

rss-es

Prolia (denosumab) by Amgen: Drug Safety Communication – FDA Investigating Risk of Severe Hypocalcemia in Patients on Dialysis

Murilo Freitas - 23:41, 21 de noviembre de 20222,015

FDA is investigating the risk of severe hypocalcemia with serious outcomes, including hospitalization and death, in patients with advanced kidney disease on dialysis treated with the osteoporosis medicine Prolia (denosumab).

http://www.fda.gov/safety/medical-product-safety-information/prolia-denosumab-amgen-drug-safety-communication-fda-investigating-risk-severe-hypocalcemia-patients

rss-es

FDA Roundup: November 22, 2022

Murilo Freitas - 21:35, 21 de noviembre de 20221,763

FDA Roundup: November 22, 2022
http://www.fda.gov/news-events/press-announcements/fda-roundup-november-22-2022

rss-es

FDA Approves First Gene Therapy to Treat Adults with Hemophilia B

Murilo Freitas - 20:33, 21 de noviembre de 20221,322

FDA Approves First Gene Therapy to Treat Adults with Hemophilia B
http://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-hemophilia-b

rss-es

FDA Roundup: November 18, 2022

Murilo Freitas - 22:00, 17 de noviembre de 2022795

FDA Roundup: November 18, 2022
http://www.fda.gov/news-events/press-announcements/fda-roundup-november-18-2022

rss-es

FDA Approves First Drug That Can Delay Onset of Type 1 Diabetes

Murilo Freitas - 22:01, 16 de noviembre de 2022935

FDA Approves First Drug That Can Delay Onset of Type 1 Diabetes
http://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-can-delay-onset-type-1-diabetes

rss-es

FDA Warns Seven Companies for Selling Dietary Supplements with Claims to Treat Cardiovascular Disease

Murilo Freitas - 16:01, 16 de noviembre de 2022759

FDA Warns Seven Companies for Selling Dietary Supplements with Claims to Treat Cardiovascular Disease
http://www.fda.gov/news-events/press-announcements/fda-warns-seven-companies-selling-dietary-supplements-claims-treat-cardiovascular-disease

rss-es

At-Home COVID-19 Antigen Tests-Take Steps to Reduce Your Risk of False Negative Results: FDA Safety Communication

Murilo Freitas - 05:00, 16 de noviembre de 2022875

The FDA recommends repeat testing following a negative result to reduce the risk that a COVID-19 infection could be missed, whether or not you have symptoms.

http://www.fda.gov/medical-devices/safety-communications/home-covid-19-antigen-tests-take-steps-reduce-your-risk-false-negative-results-fda-safety

rss-es

FDA Spurs Innovation for Human Food from Animal Cell Culture Technology

Murilo Freitas - 18:29, 15 de noviembre de 2022771

FDA Spurs Innovation for Human Food from Animal Cell Culture Technology
http://www.fda.gov/news-events/press-announcements/fda-spurs-innovation-human-food-animal-cell-culture-technology